The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)
Abstract
Study Type – Therapy (RCT) Level of Evidence 1b What’s known on the subject? and What does the study add? Both dutasteride and finasteride inhibit type 2 5α‐reductase, the dominant form of 5α‐reductase in benign prostatic tissue, making these effective treatments for BPH. In comparison with finasteride, dutasteride has a longer half‐life and leads to a greater and more consistent suppression of serum and intraprostatic DHT. EPICS is currently the only prospective, randomized, double‐blind study of finasteride vs dutasteride for BPH endpoints conducted for longer than a few months. Over a one‐year period, treatment with dutasteride and finasteride led to similar reductions in prostate volume, and improvements in peak urine flow and urinary symptoms associated with BPH in men with an enlarged prostate. Men treated with finasteride and dutasteride also experienced similar rates of adverse events over the course of one year, which suggests that inhibition of both type 1 and type 2 5α‐reductase, resulting in greater DHT suppression than type 2 inhibition alone, does not confer an increase in adverse events. Given the long‐term, progressive nature of BPH, the one‐year duration of EPICS may limit the potential to observe major differences between dutasteride and finasteride treatment. OBJECTIVE: To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months. PATIENTS AND METHODS: The Enlarged Prostate International Comparator Study was a multicentre, randomized, double‐blind, 12‐month, parallel‐group study. Men aged ≥50 years with a clinical diagnosis of BPH received once‐daily treatment with dutasteride 0.5 mg ( n = 813) or finasteride 5 mg ( n = 817). After a 4‐week placebo run‐in period, patients were randomized to receive dutasteride or finasteride for 48 weeks, followed by an optional 24‐month, open‐label phase, during which patients received dutasteride 0.5 mg once daily. The primary endpoint was change in prostate volume, and the secondary endpoints included improvement in American Urological Association Symptom Index (AUA‐SI) scores, improvement in maximum urinary flow rate (Q max ) and long‐term safety in the 24‐month open‐label phase. RESULTS: Both dutasteride and finasteride were effective at reducing prostate volume with no significant difference between the two treatments during the study. Similar reductions in mean AUA‐SI scores and Q max were also observed for men in both treatment groups. A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open‐label phase. CONCLUSION: Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q max and urinary symptoms associated with BPH in men with an enlarged prostate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular genetics of steroid 5 alpha-reductase 2 deficiency
Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato-McGinley, J., Griffin, J. E., Francke, U., Wilson, J. D., & Russell, D. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115954 · Cited by 422
Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase.
Jenkins, E. P., Andersson, S., Imperato-McGinley, J., Wilson, J. D., & Russell, D. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115574 · Cited by 395
Cited by
The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases
Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012) · Advances in Urology · doi:10.1155/2012/530121 · Cited by 333
Metadata
- Authors
- Nickel, J. C., Gilling, P., Tammela, T. L., Morrill, B., Wilson, T. H., & Rittmaster, R. S.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2011-06
- Volume
- 108
- Issue
- 3
- Pages
- 388-394
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1729580440
- Cited by
- 218
- References
- 2
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). https://app.cochat.ai/papers/10.1111/j.1464-410x.2011.10195.x
- The paper
- Nickel, J. C., Gilling, P., Tammela, T. L., Morrill, B., Wilson, T. H., & Rittmaster, R. S. (2011). Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU International. https://doi.org/10.1111/j.1464-410x.2011.10195.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.